KIT and neoplasm: Another multi-kinase inhibitor sunitinib, an anti-PDGFRα/β, VEGFR1/2/3, KIT, FLT3, CSF- b1R and RET, has been shown to decrease primary tumor proliferation and reduce tumor vasculature in cell-derived intratibial OS model in SCID mice9.